KNW - Know Labs, Inc.
After hours:
Chart Events
Continuation Wedge (Bearish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.2200 |
| Open | 1.2200 |
| Bid | 1.2100 x 800 |
| Ask | 1.2300 x 1400 |
| Day's Range | 1.2100 - 1.2700 |
| 52 Week Range | 0.8000 - 4.0000 |
| Volume | |
| Avg. Volume | 86,704 |
| Market Cap | 63.038M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Business Wire
Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring
SEATTLE, June 07, 2023--Know Labs (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, revealed the next stage in the development of its proprietary Bio-RFID™ technology – the Generation (Gen) 1 Device. Gen 1 incorporates Know Labs’ Bio-RFID sensor – which has been proven as technically feasible and stable in delivering repeatable results in measuring blood glucose when used in a lab environment – in a portable device.
- Business Wire
Know Labs’ Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy
SEATTLE, May 30, 2023--Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, "Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology." The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs’ Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference (MA
- Newsfile
Know Labs, Inc. Discusses Significant Growth of Its IP Portfolio and 2023 Goals with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - May 25, 2023) - The Stock Day Podcast welcomed Know Labs, Inc. (NYSE American: KNW) ("the Company"), an emerging developer of non-invasive medical diagnostic technology. The Company refers to its novel technology as Bio-RFID™ which directs electromagnetic energy in the form of radio waves through organic or inorganic materials to capture a unique molecular signature. CEO and Chairman of the Company, Ron Erickson, joined Stock Day host Kevin Davis.Davis began .
- Business Wire
Know Labs Joins IPBC Global 2023 to Discuss the Importance of Strategic IP Development in Maximizing Shareholder Value
SEATTLE, May 23, 2023--Know Labs (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced that Pete Conley, its Chief Financial Officer and Senior Vice President of Intellectual Property (IP), will speak at the upcoming 2023 Intellectual Property Business Congress (IPBC) Global event in June – the world’s largest gathering of leaders and decision-makers operating in the global IP market.
- Business Wire
Know Labs Furthers External Validation of Bio-RFID™ Technology with Study Published in Sensors Journal
SEATTLE, May 18, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the publication of its first peer-reviewed study in Sensors Journal. The manuscript titled, Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions—Implications for Non-Invasive Physiologic Monitoring, describes the proof-of-principle study of Know Labs’ Bio-RFID technology that quantified different analytes in vitro, p
- Business Wire
Know Labs, Inc. Reports Second Quarter FY2023 Results
SEATTLE, May 15, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023.
- Business Wire
Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2023 Results on May 15, 2023
SEATTLE, May 08, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2023 ended on March 31, 2023, on May 15, 2023, beginning at 1:30 pm PT.
- Business Wire
Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring
SEATTLE, May 05, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, "Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®." Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA.
- Business Wire
Know Labs Demonstrates Accuracy of Non-Invasive, Bio-RFID Technology with Proof-of-Principle Study
SEATTLE, April 21, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring," conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is b
- Business Wire
Know Labs Forms New Scientific Advisory Board, Appoints Respected Researchers in Medical Innovation as First Members
SEATTLE, March 22, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the establishment of a Scientific Advisory Board (SAB) comprised of distinguished researchers, innovators and experts in medical technology and human health. SAB members will advise the company and its strategic partners on advancing the company’s progress in algorithm refinement, device development, clinical trial design and research publication str
- Business Wire
Know Labs, Inc. Reports First Quarter 2023 Results
SEATTLE, February 14, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022.
- Business Wire
Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2023 Results on February 14, 2023
SEATTLE, February 07, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2023 ended on December 31, 2022, on February 14, 2023, beginning at 1:30 pm PT.
- Business Wire
Know Labs Provides Update on Strategic Partners Engaged in Data Science, Product Engineering and Regulatory Affairs to Accelerate Progress Toward FDA Application
SEATTLE, February 02, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today shared an update on its strategic partnerships with leading experts in data science, sensor technology, product design and regulatory affairs. These strategic partners collectively accelerate Know Labs’ progress toward the FDA clearance process for the world’s first non-invasive glucose monitoring medical devices.
- Business Wire
Know Labs Announces Executive Leadership Changes and Confirms 2023 Outlook
SEATTLE, January 27, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced changes to its executive leadership team. The new structure will help the Company accelerate the development and delivery of its non-invasive medical diagnostics technology, Bio-RFIDTM, and better position Know Labs for long-term growth and shareholder value creation.
- Business Wire
Know Labs, Inc. Names Ron Erickson Chief Executive Officer; Former CEO Phil Bosua Becomes a Technology Consultant to the Company
SEATTLE, January 26, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced that Ron Erickson, Founder and Chairman, has been unanimously named Chief Executive Officer by the Company’s Board of Directors, while continuing as Chairman of the Board. Former CEO Phil Bosua has stepped down as an executive officer of the Company and Board Member and will become a technology advisor and consultant to Know Labs, effective immedia
- Business Wire
Know Labs, Inc. Expands IP Leadership in Non-Invasive Diagnostics with New High Performance Glucose Sensor Patent
SEATTLE, January 04, 2023--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been granted a new foundational patent that equates the company’s Bio-RFIDTM diagnostic technology to a current reference standard for glucose monitoring, widely used by diabetes researchers, hospital labs and glucose meter manufacturers, and establishes a specific, superior benchmark range of clinical accuracy, known as the MARD or Mean Abs
- Business Wire
Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2022 Results
SEATTLE, December 20, 2022--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the quarter and fiscal year ended September 30, 2022.
- Business Wire
Know Labs, Inc. Addresses False and Incomplete Short Seller’s Claims
SEATTLE, December 20, 2022--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today addressed recent claims by a purported research firm known for fueling and participating in short-selling, which has distributed false and incomplete information about the company in an apparent effort to profit by driving down the company’s stock price.
- Business Wire
Know Labs, Inc. to Host Review of Fiscal Year 2022 Results on December 20, 2022
SEATTLE, December 14, 2022--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review updates and results for its fiscal year ended on Sept. 30, 2022, on Dec. 20, 2022, beginning at 1:30 pm PT.
- Business Wire
Know Labs Participating in Second Annual Bernstein CGM Disruptors Conference
SEATTLE, November 07, 2022--Know Labs, Inc. (NYSE AMERICAN: KNW), an emerging leader in non-invasive medical diagnostic technology, will present at the second annual Bernstein CGM Disruptors Conference www.bernsteinresearch.com on Friday, Nov. 18, 2022. At the virtual event, attendees from across the globe will gather to discuss new developments in continuous glucose monitoring technology.
- Business Wire
Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock
SEATTLE, September 20, 2022--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares. The gross proceeds from this offering, before deducting underwriting discounts and commissions and othe
